

BioCorRx to Exhibit at the 2nd Annual National Opioid Crisis Management Congress

ANAHEIM, CA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- **BioCorRx Inc. (OTCQB: BICX) (the “Company”)**, a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will host an exhibit at the 2nd Annual National Opioid Crisis Management Congress at the Omni Shoreham Hotel in Washington, DC, on September 27-28, 2018.

This conference will address the state of science in pain management, characterize the epidemiology of the opioid epidemic, and identify actions that can be taken to respond to this crisis. In addition, experts at the state and federal levels providing leadership on the opioid public health crisis will present collaborative strategic partnerships to serve the most vulnerable citizens.

Brady Granier, CEO, President, and Director of BioCorRx, stated, “We look forward to engaging with top thought leaders, as well as state and federal officials at the National Opioid Crisis Management Congress next week. Millions of Americans are suffering from opioid use disorder and the BioCorRx[®] Recovery Program is an ideal solution available now for many of those suffering, as it combines medications like naltrexone with cognitive behavioral therapy (CBT) and peer recovery support. We also look forward to discussing BICX102, our naltrexone implant in which we are seeking FDA approval and NIDA funding.”

September is National Recovery Month. Each September, the Substance Abuse and Mental Health Services Administration (SAMHSA) asks the nation to observe National Recovery Month to increase awareness and understanding of mental and substance use disorders. In honor of National Recovery Month, BioCorRx would like to again share the story of Jordan’s recovery. Jordan has been in recovery for 18 months and this is his story- <https://www.10tv.com/article/hi-tech-treatment-now-possible-opiate-addiction>. It’s important to celebrate and honor these individuals who continue their journey of recovery from substance use disorder and those who provide treatment and recovery services. Collectively, we can help to strengthen families and communities by raising awareness to those outside of the recovery community so that they can better understand the strength, courage and hard work required in addiction recovery.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx[®] Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for

alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com



Source: BioCorRx Inc